S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
NASDAQ:PRVB

Provention Bio - PRVB Stock Forecast, Price & News

$5.62
+0.34 (+6.44%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.33
$5.76
50-Day Range
$3.43
$5.62
52-Week Range
$3.18
$8.04
Volume
966,280 shs
Average Volume
631,934 shs
Market Capitalization
$359.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

Provention Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.2% Upside
$18.33 Price Target
Short Interest
Healthy
5.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.09
Upright™ Environmental Score
News Sentiment
0.21mentions of Provention Bio in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.83) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

477th out of 1,117 stocks

Pharmaceutical Preparations Industry

235th out of 550 stocks

PRVB stock logo

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Provention Bio Trading Up 6.4 %

PRVB Stock opened at $5.62 on Friday. Provention Bio has a twelve month low of $3.18 and a twelve month high of $8.04. The company has a market capitalization of $359.90 million, a P/E ratio of -3.41 and a beta of 2.45. The firm has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $5.20.

Provention Bio (NASDAQ:PRVB - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.80 million. Provention Bio had a negative net margin of 3,840.68% and a negative return on equity of 100.07%. During the same quarter in the previous year, the company posted ($0.46) earnings per share. On average, research analysts predict that Provention Bio will post -1.83 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on PRVB shares. Chardan Capital lowered their price objective on shares of Provention Bio from $22.50 to $21.00 and set a "buy" rating for the company in a research report on Friday, August 5th. HC Wainwright lowered their price objective on shares of Provention Bio from $25.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, July 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $18.33.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Earnings Preview For Provention Bio
Provention Bio Inc. Tops Q1 EPS by 11c
Provention Bio Q1 2022 Earnings Preview
See More Headlines
Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+226.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-114,430,000.00
Net Margins
-3,840.68%
Pretax Margin
-4,100.00%

Debt

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$1.23 per share

Miscellaneous

Free Float
55,651,000
Market Cap
$359.90 million
Optionable
Not Optionable
Beta
2.45














PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRVB shares.
View PRVB analyst ratings
or view top-rated stocks.

What is Provention Bio's stock price forecast for 2022?

6 equities research analysts have issued 12 month target prices for Provention Bio's stock. Their PRVB share price forecasts range from $16.00 to $21.00. On average, they predict the company's share price to reach $18.33 in the next year. This suggests a possible upside of 226.2% from the stock's current price.
View analysts price targets for PRVB
or view top-rated stocks among Wall Street analysts.

How have PRVB shares performed in 2022?

Provention Bio's stock was trading at $5.62 on January 1st, 2022. Since then, PRVB stock has increased by 0.0% and is now trading at $5.62.
View the best growth stocks for 2022 here
.

When is Provention Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PRVB earnings forecast
.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) issued its quarterly earnings results on Thursday, August, 4th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.03. The firm earned $0.75 million during the quarter, compared to analysts' expectations of $0.80 million. Provention Bio had a negative trailing twelve-month return on equity of 100.07% and a negative net margin of 3,840.68%. During the same quarter last year, the company posted ($0.46) earnings per share.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include DG Capital Management LLC (0.97%), Bioimpact Capital LLC (0.93%), Northern Trust Corp (0.81%), Rice Hall James & Associates LLC (0.35%), Renaissance Technologies LLC (0.26%) and Sigma Planning Corp (0.24%). Insiders that own company stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends
.

How do I buy shares of Provention Bio?

Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $5.62.

How much money does Provention Bio make?

Provention Bio (NASDAQ:PRVB) has a market capitalization of $359.90 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.